KRAS and colorectal carcinoma: This study aimed to determine the prevalence and clinicopathological associations of KRAS, NRAS, and BRAF mutations in a Libyan CRC cohort, as these mutations are key drivers of tumorigenesis and predictors of resistance to anti-epidermal growth factor receptor therapy.